Method for the Treatment of Multiple Sclerosis

The invention relates to the discovery that humanized antibodies to the interleukin-2 receptor (IL-2R) such as (daclizumab) are effective in treating multiple sclerosis (MS). In particular, it has been discovered that patients who have failed to respond to therapy with interferon-beta show dramatic improvement when treated with daclizumab, with patients showing both a reduction in the total number of lesions and cessation of appearance of new lesions during the treatment period. Daclizumab is effective both in combination with interferon-beta and alone.


Roland Martin (NINDS)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 7,258,859 issued 2007-08-21
U.S. Pat: 8,454,965 issued 2013-06-04
U.S. Pat: 8,298,525 issued 2012-10-30
U.S. Pat: 8,636,997 issued 2014-01-28
US Application No. 11/827,876
US Application No. 12/401,543
US Application No. 14/792,432
US Application No. 13/725,119
US Application No. 13/475,688
US Application No. 13/612,763
US Application No. 14/139,424
US Application No. 14/487,012
US Application No. 15/956,458
US Application No. 16/132,852

Licensing Contact:
Susan Ano, Ph.D.
Phone: 301-435-5515

OTT Reference No: E-143-2002-0
Updated: Aug 1, 2003